IRF8 and neoplasm: This study showed that the IRF8 promoter was frequently hypermethylated in primary breast cancers, and IRF8 served as a main downstream factor in the IFN-γ/STAT1 signaling pathway, with a possible role in enhancing the anti-tumor effect of IFN-γ.